Entyvio Side Effects
Generic name: vedolizumab
Note: This document contains side effect information about vedolizumab. Some dosage forms listed on this page may not apply to the brand name Entyvio.
Common side effects of Entyvio include: nasopharyngitis. Other side effects include: upper respiratory tract infection and fatigue. Continue reading for a comprehensive list of adverse effects.
Applies to vedolizumab: parenteral diluted solution, parenteral powder for iv infusion, parenteral reconstituted solution.
Side effects include:
Most common adverse reactions (incidence ≥3% and ≥1% higher than placebo) are: Nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities.
For Healthcare Professionals
Applies to vedolizumab: intravenous powder for injection.
The most common adverse reactions were nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.[Ref]
Uncommon (0.1% to 1%): Folliculitis[Ref]
Frequency not reported: Elevations of transaminase, elevations of bilirubin, hepatitis, ALT elevations, AST elevations[Ref]
Common (1% to 10%): Infusion related reactions (e.g., infusion site reaction, infusion site pain, infusion site irritation)
Common (1% to 10%): Influenza
Uncommon (0.1% to 1%): Bacterial sepsis, septic shock
Very common (10% or more): Arthralgia (12%)
Common (1% to 10%): Back pain, pain in extremities[Ref]
Very common (10% or more): Headache (12%)
Common (1% to 10%): Paresthesia[Ref]
Rare (less than 0.1%): Transitional cell carcinoma, carcinoid tumor of the appendix
Frequency not reported: B-cell lymphoma, breast cancer, colon cancer, malignant hepatic neoplasm, malignant lung neoplasm, malignant melanoma, lung cancer of primary neuroendocrine carcinoma, renal cancer, squamous cell carcinoma[Ref]
Common (1% to 10%): Pyrexia, fatigue[Ref]
Very common (10% or more): Nasopharyngitis (13%)
Common (1% to 10%): Upper respiratory tract infection, cough, bronchitis, influenza, sinusitis
Common (1% to 10%): Hypertension[Ref]
Frequently asked questions
- Can I drink alcohol while taking Entyvio?
- Entyvio and the COVID vaccine, what should I know?
- Does Entyvio increase the risk of cancer?
- Does Entyvio cause joint pain?
- Is Entyvio used to treat ulcerative colitis?
- Is Entyvio used to treat Crohn’s disease?
- How is Entyvio administered?
- How long does it take Entyvio to start working?
- Can Entyvio cause hair loss?
More about Entyvio (vedolizumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (137)
- Drug images
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: selective immunosuppressants
- En español
Related treatment guides
1. Product Information. Entyvio (vedolizumab). Takeda Pharmaceuticals America. 2014.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.